JP5248739B2 - 腸溶性調製物 - Google Patents
腸溶性調製物 Download PDFInfo
- Publication number
- JP5248739B2 JP5248739B2 JP2004541451A JP2004541451A JP5248739B2 JP 5248739 B2 JP5248739 B2 JP 5248739B2 JP 2004541451 A JP2004541451 A JP 2004541451A JP 2004541451 A JP2004541451 A JP 2004541451A JP 5248739 B2 JP5248739 B2 JP 5248739B2
- Authority
- JP
- Japan
- Prior art keywords
- gel material
- material composition
- acid
- enteric
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title description 9
- 239000000499 gel Substances 0.000 claims description 94
- 239000000463 material Substances 0.000 claims description 93
- 229920000642 polymer Polymers 0.000 claims description 74
- 239000000203 mixture Substances 0.000 claims description 54
- 239000007901 soft capsule Substances 0.000 claims description 46
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 34
- 108010010803 Gelatin Proteins 0.000 claims description 27
- 229920000159 gelatin Polymers 0.000 claims description 27
- 239000008273 gelatin Substances 0.000 claims description 27
- 235000019322 gelatine Nutrition 0.000 claims description 27
- 235000011852 gelatine desserts Nutrition 0.000 claims description 27
- 239000004014 plasticizer Substances 0.000 claims description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 239000003513 alkali Substances 0.000 claims description 19
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 17
- 239000001069 triethyl citrate Substances 0.000 claims description 17
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 17
- 235000013769 triethyl citrate Nutrition 0.000 claims description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229910001868 water Inorganic materials 0.000 claims description 15
- 229920003169 water-soluble polymer Polymers 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 7
- 229920001800 Shellac Polymers 0.000 claims description 7
- 239000004208 shellac Substances 0.000 claims description 7
- 235000013874 shellac Nutrition 0.000 claims description 7
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 7
- 229940113147 shellac Drugs 0.000 claims description 7
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 6
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- 238000005266 casting Methods 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- -1 citrate ester Chemical class 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 40
- 239000003921 oil Substances 0.000 description 35
- 235000019198 oils Nutrition 0.000 description 35
- 238000011049 filling Methods 0.000 description 29
- 238000009507 drug disintegration testing Methods 0.000 description 23
- 238000009506 drug dissolution testing Methods 0.000 description 23
- 238000000576 coating method Methods 0.000 description 19
- 239000002585 base Substances 0.000 description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 16
- 239000011248 coating agent Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 10
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 229920003139 Eudragit® L 100 Polymers 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000003549 soybean oil Substances 0.000 description 8
- 235000012424 soybean oil Nutrition 0.000 description 8
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 229960000503 bisacodyl Drugs 0.000 description 7
- 239000007902 hard capsule Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 6
- 238000009505 enteric coating Methods 0.000 description 6
- 239000002702 enteric coating Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229960004343 alendronic acid Drugs 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 239000008173 hydrogenated soybean oil Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000004904 shortening Methods 0.000 description 5
- 239000000945 filler Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 4
- 229960000907 methylthioninium chloride Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- 239000006000 Garlic extract Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 235000020706 garlic extract Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229960000381 omeprazole Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 240000002234 Allium sativum Species 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical class COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002152 aqueous-organic solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009498 subcoating Methods 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000011240 wet gel Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41518702P | 2002-10-01 | 2002-10-01 | |
| US60/415,187 | 2002-10-01 | ||
| PCT/US2003/020579 WO2004030658A1 (en) | 2002-10-01 | 2003-06-27 | Enteric composition for the manufacture of soft capsule wall |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006505542A JP2006505542A (ja) | 2006-02-16 |
| JP2006505542A5 JP2006505542A5 (https=) | 2006-08-17 |
| JP5248739B2 true JP5248739B2 (ja) | 2013-07-31 |
Family
ID=32069824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004541451A Expired - Lifetime JP5248739B2 (ja) | 2002-10-01 | 2003-06-27 | 腸溶性調製物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8685445B2 (https=) |
| EP (2) | EP1545475B1 (https=) |
| JP (1) | JP5248739B2 (https=) |
| CN (1) | CN1688294A (https=) |
| AU (1) | AU2003299191A1 (https=) |
| CA (1) | CA2500663C (https=) |
| CY (1) | CY1118258T1 (https=) |
| DK (2) | DK1545475T3 (https=) |
| ES (2) | ES2500316T3 (https=) |
| HU (1) | HUE031650T2 (https=) |
| MX (1) | MXPA05003524A (https=) |
| PT (2) | PT2772250T (https=) |
| SI (2) | SI2772250T1 (https=) |
| WO (1) | WO2004030658A1 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070082046A1 (en) * | 2005-10-11 | 2007-04-12 | Banner Pharmacaps, Inc. | Enteric valproic acid |
| CN101351196B (zh) | 2005-10-26 | 2013-07-03 | 班纳制药公司 | 作为胶囊填充物的基于亲脂性载体的双重控释基质系统 |
| CA2627292C (en) | 2005-10-26 | 2012-04-17 | Banner Pharmacaps, Inc. | Hydrophilic vehicle-based dual controlled release matrix system |
| US20070148248A1 (en) * | 2005-12-22 | 2007-06-28 | Banner Pharmacaps, Inc. | Gastric reflux resistant dosage forms |
| JP5183104B2 (ja) * | 2006-06-19 | 2013-04-17 | 森下仁丹株式会社 | 口臭除去用多重ソフトカプセル |
| GB0706178D0 (en) * | 2007-03-29 | 2007-05-09 | Univ Aston | Enteric pharmaceutical capsules |
| WO2009064814A2 (en) | 2007-11-12 | 2009-05-22 | Pharmaceutics International, Inc. | Tri-molecular complexes and their use in drug delivery systems |
| WO2009062356A1 (en) * | 2007-11-13 | 2009-05-22 | Shanghai Huiyuan Vegetal Capsule Co., Ltd | Non-gelatin enteric hard capsule shell and preparation method thereof |
| EP2293782B1 (en) | 2008-05-06 | 2015-08-12 | Dexcel Pharma Technologies Ltd. | Stable benzimidazole formulation |
| US8309107B2 (en) | 2008-10-06 | 2012-11-13 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
| CN102307576A (zh) | 2008-12-15 | 2012-01-04 | 班纳制药公司 | 用于增强水不溶性活性剂的释放和吸收的方法 |
| WO2010117873A2 (en) | 2009-04-06 | 2010-10-14 | Banner Pharmacaps, Inc. | Progesterone solutions for increased bioavailability |
| US20130115285A1 (en) * | 2010-02-12 | 2013-05-09 | Eric H. Van Ness | Enteric coating compositions and methods of making and using the same |
| EP3354335A1 (en) | 2010-10-26 | 2018-08-01 | Capsugel Belgium NV | Bulk enteric capsule shells |
| EP3446713A3 (en) | 2012-05-02 | 2019-05-15 | Capsugel Belgium NV | Aqueous dispersions of controlled release polymers and shells and capsules thereof |
| EP2968081A4 (en) | 2013-03-15 | 2016-08-10 | Banner Life Sciences Llc | MOLLE ENTERIC CAPSULES NOT CONTAINING GELATIN |
| CA2909591C (en) * | 2013-04-23 | 2017-03-28 | Zx Pharma, Llc | Enteric coated multiparticulate composition with proteinaceous subcoat |
| US9504656B2 (en) | 2013-10-21 | 2016-11-29 | Banner Life Sciences, LLC | Pharmaceutical compositions for poorly soluble active ingredients |
| CA2926335C (en) | 2013-10-30 | 2021-11-23 | Banner Life Sciences Llc | Enteric soft capsules comprising polyunsaturated fatty acids |
| US20160256399A1 (en) | 2013-11-04 | 2016-09-08 | Capsugel Belgium Nv | Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole |
| ES2713157T3 (es) | 2014-02-28 | 2019-05-20 | Banner Life Sciences Llc | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10772842B2 (en) | 2015-01-09 | 2020-09-15 | Patheon Softgels Inc. | Abuse-deterrent opioids |
| US10182992B2 (en) | 2014-04-07 | 2019-01-22 | Patheon Softgels Inc. | Abuse-deterrent controlled release formulations |
| WO2015195989A1 (en) * | 2014-06-20 | 2015-12-23 | Banner Life Sciences Llc | Enteric soft capsule compositions |
| US20150366814A1 (en) | 2014-06-23 | 2015-12-24 | Banner Life Sciences Llc | All-natural enteric soft capsules comprising active ingredients |
| WO2015200563A1 (en) * | 2014-06-26 | 2015-12-30 | Banner Life Sciences Llc | Enhanced bioavailability of polysaturated fatty acids |
| US9895333B2 (en) | 2014-06-26 | 2018-02-20 | Patheon Softgels Inc. | Enhanced bioavailability of polyunsaturated fatty acids |
| US10471152B2 (en) | 2014-08-29 | 2019-11-12 | Capsugel Belgium Nv | Colloidal dispersion comprising HPMCAS |
| KR101917334B1 (ko) | 2014-10-06 | 2018-11-09 | 후지 캡슐 가부시키가이샤 | 장용성 심리스 소프트 캡슐의 제조 방법 |
| CA2960631C (en) | 2014-10-06 | 2018-06-05 | Fuji Capsule Co., Ltd. | Method of manufacturing enteric soft capsule |
| AU2015328676B2 (en) * | 2014-10-08 | 2017-07-20 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US10363254B2 (en) * | 2015-03-31 | 2019-07-30 | University Of Vermont And State Agricultural College | Methods for treating cryptosporidiosis using triazolopyridazines |
| US10182993B2 (en) | 2015-04-06 | 2019-01-22 | Patheon Softgels Inc. | Compositions for colonic delivery of drugs |
| WO2017136617A1 (en) | 2016-02-04 | 2017-08-10 | Cinrx Pharma, Llc | Deuterated domperidone compositions and methods for therapy of disorders |
| US11364226B2 (en) | 2017-06-30 | 2022-06-21 | Cinrx Pharma, Llc | Deuterated domperidone compositions, methods, and preparation |
| PL239878B1 (pl) | 2016-03-30 | 2022-01-24 | Gdanski Univ Medyczny | Wodna kompozycja oraz sposób wytwarzania dojelitowych elastycznych filmów do sporządzania kapsułek z wodnej kompozycji oraz dojelitowy elastyczny film do sporządzania kapsułek miękkich |
| NL2017219B1 (en) * | 2016-07-22 | 2018-01-30 | Rousselot B V | Low cross-linking gelatine |
| EA201992116A1 (ru) | 2017-03-08 | 2020-01-29 | СИНРКС ФАРМА, ЭлЭлСи | Фармацевтические составы флороглюцинола и триметилфлороглюцинола |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| AU2019236217B2 (en) | 2018-03-15 | 2025-02-20 | R.P. Scherer Technologies, Llc | Enteric softgel capsules |
| CN108619523B (zh) * | 2018-03-23 | 2020-06-30 | 浙江工业大学 | 一种可用于快速热塑包衣制剂的包衣膜片及其制备方法 |
| WO2020144591A2 (en) * | 2019-01-09 | 2020-07-16 | Antony Benny | Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use for the treatment of health disorders |
| CN109566829A (zh) * | 2019-02-11 | 2019-04-05 | 广东国方医药科技有限公司 | 牡丹籽油肠溶凝胶糖果及其制备方法 |
| US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
| US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
| US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
| US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
| MX2021013488A (es) | 2019-05-07 | 2021-12-10 | Bausch Health Ireland Ltd | Formulaciones liquidas de dosis oral de metilnaltrexona. |
| US20220249455A1 (en) * | 2019-07-15 | 2022-08-11 | R.P. Scherer Technologies, Llc | Enteric proton pump inhibitor softgel capsule |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| WO2021224138A1 (en) | 2020-05-02 | 2021-11-11 | Bausch Health Ireland Limited | Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone |
| CA3119012C (en) * | 2021-05-18 | 2023-10-17 | Gelentroceutics Inc. | Formulation of intrinsically acid-resistant vegetarian-based and gelatin-based soft gel capsules for pharmaceutical/nutraceutical products |
| US20250387338A1 (en) | 2022-06-21 | 2025-12-25 | Nutrition & Biosciences Usa 1, Llc | Film forming delayed/enteric formulations for hard shell capsules, films and coatings |
| CN121263207A (zh) * | 2023-06-06 | 2026-01-02 | R·P·谢勒技术有限公司 | 氨溴索液体调配物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826666A (en) * | 1972-07-20 | 1974-07-30 | Parke Davis & Co | Enteric capsules |
| DE2340060A1 (de) * | 1973-08-08 | 1975-02-20 | Scherer Gmbh R P | Magensaftresistente gelatinekapseln und verfahren zu deren herstellung |
| US4138013A (en) * | 1976-08-27 | 1979-02-06 | Parke, Davis & Company | Enteric capsules |
| GR78492B (https=) | 1982-03-26 | 1984-09-27 | Warner Lambert Co | |
| US4790881A (en) * | 1982-03-26 | 1988-12-13 | Warner-Lambert Company | Molded hydrophilic polymer |
| DE3222476A1 (de) | 1982-06-15 | 1983-12-15 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Magensaftresistente weichgelatinekapseln und verfahren zu ihrer herstellung |
| US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4500453A (en) * | 1984-06-29 | 1985-02-19 | Dynagel Incorporated | Cross-linked protein composition using aluminum salts of acetic acid |
| US4816259A (en) | 1987-02-12 | 1989-03-28 | Chase Chemical Company, L.P. | Process for coating gelatin capsules |
| US5194464A (en) * | 1988-09-27 | 1993-03-16 | Takeda Chemical Industries, Ltd. | Enteric film and preparatoin thereof |
| US6482516B1 (en) | 1993-07-20 | 2002-11-19 | Banner Pharmacaps, Inc. | Enrobed tablet |
| US5146730A (en) | 1989-09-20 | 1992-09-15 | Banner Gelatin Products Corp. | Film-enrobed unitary-core medicament and the like |
| US5330759A (en) | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
| KR20010012402A (ko) * | 1997-05-09 | 2001-02-15 | 세이지 파마슈티칼스, 인크. | 안정한 약제학적 경구 투여형 |
| US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
| UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US6193999B1 (en) * | 1999-03-01 | 2001-02-27 | Banner Pharmacaps, Inc. | Gum acacia substituted soft gelatin capsules |
| DE19922537A1 (de) | 1999-05-10 | 2000-11-16 | Roland Bodmeier | Darreichungsform zur Applikation in Körperöffnungen |
| ATE284205T1 (de) * | 1999-10-01 | 2004-12-15 | Natco Pharma Ltd | Magensaftresistente gelartige weichkapsel |
| EP1184033A1 (en) | 2000-09-01 | 2002-03-06 | Warner-Lambert Company | Pectin film compositions |
| AU2003274683A1 (en) * | 2002-08-02 | 2004-02-23 | Scitech Centre | NOVEL pH DEPENDENT ROBUST ENTERIC POLYMERIC CONTAINER, AN IMPROVEMENT OVER EXISTING ENTERIC DOSAGE FORMS. |
-
2003
- 2003-06-27 DK DK03742336.5T patent/DK1545475T3/da active
- 2003-06-27 ES ES03742336.5T patent/ES2500316T3/es not_active Expired - Lifetime
- 2003-06-27 EP EP03742336.5A patent/EP1545475B1/en not_active Expired - Lifetime
- 2003-06-27 WO PCT/US2003/020579 patent/WO2004030658A1/en not_active Ceased
- 2003-06-27 MX MXPA05003524A patent/MXPA05003524A/es active IP Right Grant
- 2003-06-27 US US10/529,984 patent/US8685445B2/en active Active
- 2003-06-27 DK DK14170492.4T patent/DK2772250T3/en active
- 2003-06-27 CN CNA038235579A patent/CN1688294A/zh active Pending
- 2003-06-27 HU HUE14170492A patent/HUE031650T2/en unknown
- 2003-06-27 PT PT141704924T patent/PT2772250T/pt unknown
- 2003-06-27 AU AU2003299191A patent/AU2003299191A1/en not_active Abandoned
- 2003-06-27 SI SI200332504A patent/SI2772250T1/sl unknown
- 2003-06-27 ES ES14170492.4T patent/ES2609059T3/es not_active Expired - Lifetime
- 2003-06-27 EP EP14170492.4A patent/EP2772250B1/en not_active Expired - Lifetime
- 2003-06-27 SI SI200332379T patent/SI1545475T1/sl unknown
- 2003-06-27 PT PT37423365T patent/PT1545475E/pt unknown
- 2003-06-27 JP JP2004541451A patent/JP5248739B2/ja not_active Expired - Lifetime
- 2003-06-27 CA CA2500663A patent/CA2500663C/en not_active Expired - Lifetime
-
2014
- 2014-03-28 US US14/228,387 patent/US9433585B2/en not_active Expired - Fee Related
-
2016
- 2016-11-21 CY CY20161101198T patent/CY1118258T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05003524A (es) | 2005-10-04 |
| ES2500316T3 (es) | 2014-09-30 |
| EP2772250A1 (en) | 2014-09-03 |
| HUE031650T2 (en) | 2017-07-28 |
| US20060165778A1 (en) | 2006-07-27 |
| US20140348879A1 (en) | 2014-11-27 |
| DK2772250T3 (en) | 2016-12-05 |
| AU2003299191A1 (en) | 2004-04-23 |
| JP2006505542A (ja) | 2006-02-16 |
| CY1118258T1 (el) | 2017-06-28 |
| US9433585B2 (en) | 2016-09-06 |
| CA2500663C (en) | 2013-05-28 |
| SI1545475T1 (sl) | 2014-10-30 |
| CN1688294A (zh) | 2005-10-26 |
| EP1545475A1 (en) | 2005-06-29 |
| EP2772250B1 (en) | 2016-09-28 |
| US8685445B2 (en) | 2014-04-01 |
| EP1545475B1 (en) | 2014-07-16 |
| CA2500663A1 (en) | 2004-04-15 |
| PT1545475E (pt) | 2014-09-16 |
| PT2772250T (pt) | 2017-01-02 |
| ES2609059T3 (es) | 2017-04-18 |
| WO2004030658A1 (en) | 2004-04-15 |
| DK1545475T3 (da) | 2014-07-28 |
| SI2772250T1 (sl) | 2017-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5248739B2 (ja) | 腸溶性調製物 | |
| US10874619B2 (en) | Acid resistant capsules | |
| JP6626712B2 (ja) | 放出制御ポリマーの水性分散液並びにそのシェル及びカプセル | |
| JP7198205B2 (ja) | 腸溶性硬質カプセル | |
| JP5489471B2 (ja) | Ｐｅｇ充填硬質カプセル剤のバンドシール | |
| KR20230106641A (ko) | 지연 방출 소프트겔 캡슐 | |
| WO2009125483A1 (ja) | 硬質カプセル剤 | |
| CN112566668B (zh) | 肠溶性硬胶囊 | |
| JP7719609B2 (ja) | 腸溶性硬質カプセル | |
| US9254270B2 (en) | Enteric soft capsules | |
| JPWO2009125485A1 (ja) | 硬質カプセル剤 | |
| TW202412746A (zh) | 多層構造腸溶性硬質膠囊 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060517 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060627 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060627 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091215 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100312 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100615 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100706 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130411 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5248739 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160419 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |